Institutional members access full text with Ovid®

Share this article on:

Gadofosveset-Enhanced Magnetic Resonance Angiography of the Thoracic Vasculature in the Equilibrium Phase: Feasibility and Impact of Dose

Kim, Charles Y. MD; Heye, Tobias MD; Bashir, Mustafa R. MD; Gebhard, Thomas A. MD; Merkle, Elmar M MD

Journal of Computer Assisted Tomography: September/October 2013 - Volume 37 - Issue 5 - p 732–736
doi: 10.1097/RCT.0b013e318299dde9
Thoracic and Cardiovascular Imaging

Objective The objectives of this study were to evaluate the feasibility of gadofosveset-enhanced magnetic resonance angiography (MRA) of the thoracic vasculature in the equilibrium phase and to determine the impact of gadofosveset dose on imaging quality.

Methods Thirty healthy volunteers were randomized to receive a dose of 0.03, 0.02, or 0.01 mmol/kg of gadofosveset for MRA at 3 T in the equilibrium phase. Two radiologists assessed the central veins, the pulmonary arteries, and the thoracic aorta. Quantitative assessments were also performed.

Results At 0.03 and 0.02 mmol/kg, all vessel segments were rated as adequate. At a dose of 0.01 mmol/kg, less than 10% of vascular segments were collectively rated as inadequate. The signal-to-noise ratio and contrast-to-noise ratio were significantly lower in all segments at 0.01 mmol/kg compared with higher doses.

Conclusions Gadofosveset-enhanced MRA of the thoracic vessels in the equilibrium phase in healthy volunteers resulted in adequate vessel visualization, even when dose reduction was performed.

This trial was registered with, identifier NCT01431300.

From the *Department of Radiology, Duke University Medical Center, Durham, NC; and †Department of Radiology, University Hospital of Basel, Basel, Switzerland.

Received for publication February 27, 2013; accepted May 1, 2013.

Reprints: Charles Y. Kim, MD, Department of Radiology, Duke University Medical Center, Box 3808, Durham, NC 27710 (e-mail:

This investigator-initiated study was sponsored by Lantheus Medical Imaging, Billerica, MA.

C.Y.K. was a member of the Lantheus Medical Imaging Speaker Bureau. No other authors report any conflicts of interest.

Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved.